Novel therapeutic strategies for AML in 2012 Journal Article

Author: Tallman, M. S.
Article Title: Novel therapeutic strategies for AML in 2012
Abstract: During the last four decades, much progress has been made in understanding the molecular pathogenesis of acute myeloid leukemia and in identifying prognostic factors predictive of outcome. However, progress in therapy has been much slower. Since the initial description of the combination of an anthracycline and cytarabine for induction, few major advances have changed the standard of care. Furthermore, these few advances apply to younger patients and those with inherently more favorable disease biology. Intensification of post-remission cytarabine improves the cure rate of patients in first complete remission (CR). Daunorubicin dose intensification improves outcome in younger patients. Finally, allogeneic hematopoietic cell transplantation is an effective strategy for many patients in first CR. The discovery of drugs with novel mechanisms of action which are directly at specific molecular targets is among the most exciting areas of research and holds great promise for the development of effective treatment. © W. S. Maney & Son Ltd 2012.
Keywords: treatment response; middle aged; survival rate; unclassified drug; acute granulocytic leukemia; mutation; leukemia, myeloid, acute; sorafenib; drug dose comparison; drug dose reduction; treatment duration; antineoplastic agents; cytarabine; drug megadose; etoposide; cytogenetics; hematopoietic stem cell transplantation; drug discovery; health care quality; acute leukemia; drug research; drug mechanism; histone methyltransferase; daunorubicin; remission induction; allogeneic hematopoietic stem cell transplantation; optimal drug dose; anthracycline; trend study; treatment contraindication; clofarabine; predictive value; induction chemotherapy; gemtuzumab ozogamicin; leukemia remission; core binding factor; molecular pathology; molecularly targeted therapy; antisense oligonucleotide; x linked inhibitor of apoptosis; induction and consolidation; new agents; consolidation chemotherapy; methyltransferase inhibitor; cpx 351; elacytarabine; sapacitabine
Journal Title: Hematology
Volume: 17
Issue: Suppl. 1
ISSN: 1024-5332
Publisher: Maney Publishing  
Date Published: 2012-04-01
Start Page: S43
End Page: S46
Language: English
DOI: 10.1179/102453312x13336169155457
PROVIDER: scopus
PUBMED: 22507777
Notes: --- - "Export Date: 1 May 2012" - "CODEN: HMATF" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Martin Stuart Tallman
    408 Tallman